Equity Profile
Pre-Earnings Brief
Neurocrine Biosciences (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases. With a market cap of $13 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs through innovative therapies.
EPS
Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
Total revenue reflects the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+31.75%
Avg Stock Reaction
+2.44%
In Q4 2025, Neurocrine reported an EPS of $1.88, exceeding expectations. However, the stock experienced a slight decline the following day.
Management Promises & Guidance
Analysts expect Neurocrine to maintain its strong performance with an EPS of $1.71 and revenue of $771 million this quarter. The company has consistently beaten EPS estimates in the past.
Bull Case
If Neurocrine exceeds expectations, it could signal strong demand for its therapies and further validate its growth strategy.
Bear Case
Conversely, any signs of slowing sales or increased competition could lead to a reassessment of the company's growth prospects.
EPS
$1.71Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$771MTotal revenue reflects the company's sales performance and market demand for its products.
Expectations
The print will turn on these two things.
Q1
Will the EPS exceed the consensus estimate of $1.71?
A beat on EPS could reinforce investor confidence and lead to a positive stock reaction.
Q2
What are the revenue expectations compared to the consensus of $771 million?
Revenue performance will indicate market demand for Neurocrine's products and overall business health.
Edge
Why consensus could be wrong
The consensus may underestimate Neurocrine's ability to capture market share in its therapeutic areas, especially given recent product launches.
Supporting Evidence
Neurocrine has consistently beaten EPS estimates, indicating stronger-than-expected performance.
Recent trends in the healthcare sector show increasing demand for neurological treatments.
The company's robust pipeline may not be fully reflected in current revenue expectations.
Key Risk
If revenue comes in significantly above $800 million, it could challenge the current bearish sentiment.
Edge
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will reflect the company's ability to sustain growth amid market challenges.
Bull Confirmed If
An EPS of $1.80 or higher would confirm strong demand and operational efficiency.
Bear Confirmed If
An EPS below $1.50 would raise concerns about growth and market competitiveness.
Pre-Earnings Positioning
Implied Move
±4.2%
Historical Avg
±2.9%
The options market is pricing in a moderate move, indicating uncertainty around the earnings report.
Options are pricing ±5.4% while NBIX has averaged ±2.9% over the last 8 prints — setup is pricing rich.
30d HV
27.0%
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Neurocrine beats expectations, history suggests the stock could rise by about 2.44%, confirming strong operational performance.
In-Line / Cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss on EPS could lead to a decline, with historical patterns suggesting a potential drop of around 2.44%.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
LOEWS CORP